Breaking News Instant updates and real-time market news.

KMB

Kimberly-Clark

$131.12

-0.37 (-0.28%)

, ACN

Accenture

$189.95

0.34 (0.18%)

14:25
11/11/19
11/11
14:25
11/11/19
14:25

Kimberly-Clark moving some ad duties to Accenture from WPP, WSJ says

Kimberly-Clark (KMB) has tapped Accenture Interactive (ACN) as the lead creative agency for its baby and child-care products, the Wall Street Journal's Nat Ives reports. The business is Accenture Interactive's first major win pitching with Droga5, the creative ad agency that Accenture bought earlier this year and made part of the business, Ives notes. Accenture Interactive competed in a review for the business, while the incumbent WPP (WPP) successfully defended its role in the Asia-Pacific region and Canada, the author says. WPP's Mindshare agency will also still handle the lion's share of Kimberly-Clark's media duties globally, Ives notes. Reference Link

KMB

Kimberly-Clark

$131.12

-0.37 (-0.28%)

ACN

Accenture

$189.95

0.34 (0.18%)

WPP

WPP

$64.60

-0.01 (-0.02%)

  • 11

    Nov

  • 19

    Nov

  • 19

    Dec

  • 23

    Jan

KMB Kimberly-Clark
$131.12

-0.37 (-0.28%)

10/22/19
DBAB
10/22/19
UPGRADE
Target $124
DBAB
Hold
Kimberly-Clark upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank analyst Stephen Powers upgraded Kimberly-Clark to Hold from Sell with a $124 price target.
09/27/19
BOFA
09/27/19
UPGRADE
Target $155
BOFA
Buy
Kimberly-Clark upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Olivia Tong upgraded Kimberly-Clark to Buy with a price target of $155, citing her forecast of improving organic sales growth and margin. The analyst believes that the company can benefit "disproportionately" from lower raw mateical costs, particularly pulp, which she estimates adding a $200M tailwind over the next 12 months. Tong adds that Kimberly-Clark offers an opportunity in terms of its relative valuation and expected earnings improvement.
09/27/19
BOFA
09/27/19
UPGRADE
BOFA
Buy
Kimberly-Clark upgraded to Buy from Neutral at BofA/Merrill
10/23/19
DBAB
10/23/19
UPGRADE
Target $124
DBAB
Hold
Deutsche Bank upgrades Kimberly-Clark to Hold on expectations reset
Deutsche Bank analyst Steve Powers upgraded Kimberly-Clark last night to Hold from Sell with a price target of $124, up from $123. Following the company's Q3 results, the analyst believes market expectations are now more aligned with his own for fiscal 2020. Further, lower commodity costs are allowing Kimberly-Clark to make more strategic investments this year than originally planned, Powers tells investors in a research note.
ACN Accenture
$189.95

0.34 (0.18%)

09/27/19
CANT
09/27/19
NO CHANGE
Target $215
CANT
Overweight
Accenture price target raised to $215 from $202 at Cantor Fitzgerald
Cantor Fitzgerald analyst Joseph Foresi raised his price target for Accenture to $215 from $202 saying the company reported "strong" fiscal Q4 results and issued "solid" guidance. Accenture remains well positioned to take market share in the outsourcing industry, says the analyst, who maintains an Overweight rating on the shares.
09/27/19
BMOC
09/27/19
NO CHANGE
Target $200
BMOC
Market Perform
Accenture price target raised to $200 from $195 at BMO Capital
BMO Capital analyst Keith Bachman raised his price target on Accenture to $200 after its in-line Q4 results and "positive" bookings. The analyst keeps his Market Perform rating however, saying the bookings growth was driven by outsourcing, while the company's consulting revenue on constant currency was "flat". Given the latest growth metrics, Bachman says the valuation on Accenture is not compelling.
09/30/19
COWN
09/30/19
NO CHANGE
Target $205
COWN
Outperform
Accenture price target raised to $205 from $195 at Cowen
Cowen analyst Bryan Bergin raised his price target on Accenture to $205 from $195. The analyst increased his target despite expectations for more moderate earnings growth and Consulting trends that may weigh on the magnitude of beats. He believes that will provide a more challenging setup but investors continue to demonstrate a willingness to pay a premium for its quality and consistency. Bergin maintained his Outperform rating on Accenture shares.
09/26/19
STFL
09/26/19
NO CHANGE
STFL
Accenture Q4 results, FY20 guidance in-line, says Stifel
Stifel analyst David Grossman maintained a Buy rating and $203 price target on Accenture after the company reported its Q4 earnings results and gave FY20 guidance, which the analyst noted were in-line in a report titled 'No News is Good News and a Reminder Why This is a Best in Class Asset.' Grossman lauded Accenture's "remarkable consistent" financial performance, and said he did not foresee any near-term changes to the fundamentals, and continued to "recommend opportunistic purchase on sustained weakness."
WPP WPP
$64.60

-0.01 (-0.02%)

12/13/18
BOFA
12/13/18
UPGRADE
BOFA
Neutral
WPP upgraded to Neutral from Underperform at BofA/Merrill
BofA/Merrill analyst Adrien de Saint Hilaire upgraded WPP to Neutral citing valuation and reduced topline risks.
04/01/19
DBAB
04/01/19
UPGRADE
DBAB
Buy
WPP upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded WPP to Buy from Hold saying the stock "looks too cheap." Just delivering on guidance will be enough to re-rate shares higher given the current low expectations, Deutsche Bank says in a research note.
04/29/19
LEHM
04/29/19
UPGRADE
LEHM
Overweight
WPP upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Julien Roch upgraded WPP to Overweight from Equal Weight and raised his price target for the shares to 11 pounds from 10 pounds. The company's organic growth is "good enough" and not getting worse, while the Kantar disposal is a catalyst, Roch tells investors in a research note. He has confidence in management's turnaround strategy and views WPP's current valuation as cheap.

TODAY'S FREE FLY STORIES

PLMR

Palomar

20:27
12/08/19
12/08
20:27
12/08/19
20:27
Recommendations
Palomar analyst commentary  »

Palomar price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

ASAZY

Assa Abloy

$0.00

(0.00%)

20:23
12/08/19
12/08
20:23
12/08/19
20:23
Downgrade
Assa Abloy rating change  »

Assa Abloy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RXEEY

Rexel

$0.00

(0.00%)

20:23
12/08/19
12/08
20:23
12/08/19
20:23
Upgrade
Rexel rating change  »

Rexel upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TATYY

Tate & Lyle

$0.00

(0.00%)

20:22
12/08/19
12/08
20:22
12/08/19
20:22
Upgrade
Tate & Lyle rating change  »

Tate & Lyle upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUO

AU Optronics

$0.00

(0.00%)

20:20
12/08/19
12/08
20:20
12/08/19
20:20
Upgrade
AU Optronics rating change  »

AU Optronics upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPL

LG Display

$6.22

0.115 (1.89%)

20:17
12/08/19
12/08
20:17
12/08/19
20:17
Upgrade
LG Display rating change  »

LG Display upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

ETNB

89bio

$28.38

0.86 (3.13%)

20:16
12/08/19
12/08
20:16
12/08/19
20:16
Initiation
89bio initiated  »

89bio initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANIOY

Acerinox

$0.00

(0.00%)

20:15
12/08/19
12/08
20:15
12/08/19
20:15
Upgrade
Acerinox rating change  »

Acerinox upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

20:15
12/08/19
12/08
20:15
12/08/19
20:15
Conference/Events
Blueprint Medicines to hold an anlayst and investor event »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

TLSNY

Telia

$0.00

(0.00%)

20:14
12/08/19
12/08
20:14
12/08/19
20:14
Downgrade
Telia rating change  »

Telia downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARWR

Arrowhead

$67.25

1.705 (2.60%)

20:13
12/08/19
12/08
20:13
12/08/19
20:13
Recommendations
Arrowhead analyst commentary  »

Arrowhead price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARGX

Argenx

$147.31

-2.56 (-1.71%)

20:08
12/08/19
12/08
20:08
12/08/19
20:08
Recommendations
Argenx analyst commentary  »

Argenx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

STC

Stewart

$43.16

0.28 (0.65%)

19:56
12/08/19
12/08
19:56
12/08/19
19:56
Downgrade
Stewart rating change  »

Stewart downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FAF

First American

$63.05

(0.00%)

19:55
12/08/19
12/08
19:55
12/08/19
19:55
Downgrade
First American rating change  »

First American downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

PFSI

PennyMac Financial

$33.91

0.12 (0.36%)

19:54
12/08/19
12/08
19:54
12/08/19
19:54
Downgrade
PennyMac Financial rating change  »

PennyMac downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

18:40
12/08/19
12/08
18:40
12/08/19
18:40
Recommendations
Agios Pharmaceuticals analyst commentary at Piper Jaffray »

Agios' initial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

18:34
12/08/19
12/08
18:34
12/08/19
18:34
Recommendations
Blueprint Medicines analyst commentary at Piper Jaffray »

Piper says 'jury…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

18:29
12/08/19
12/08
18:29
12/08/19
18:29
Recommendations
Fate Therapeutics analyst commentary at Piper Jaffray »

FT500 data validates Fate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCKT

Rocket Pharmaceuticals

$22.37

2.61 (13.21%)

18:05
12/08/19
12/08
18:05
12/08/19
18:05
Hot Stocks
Rocket says Phase 1 trial establishes feasibility of commercial Process B for FA »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

ARGX

Argenx

$147.31

-2.56 (-1.71%)

, JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

18:03
12/08/19
12/08
18:03
12/08/19
18:03
Recommendations
Argenx, Johnson & Johnson analyst commentary at Piper Jaffray »

Argenx data on…

ARGX

Argenx

$147.31

-2.56 (-1.71%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 16

    Dec

  • 21

    Jan

BLUE

Bluebird Bio

$79.51

-1.24 (-1.54%)

, JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

17:58
12/08/19
12/08
17:58
12/08/19
17:58
Recommendations
Bluebird Bio, Johnson & Johnson, Amgen, Bristol-Myers, Regeneron analyst commentary at Piper Jaffray »

Piper says…

BLUE

Bluebird Bio

$79.51

-1.24 (-1.54%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

AMGN

Amgen

$233.74

0.3 (0.13%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

REGN

Regeneron

$372.26

4.02 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

  • 21

    Jan

BGNE

BeiGene

$186.89

-2.3 (-1.22%)

17:50
12/08/19
12/08
17:50
12/08/19
17:50
Hot Stocks
BeiGene announces data from two clinical trials of Brukinsa at ASH meeting »

BeiGene announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 27

    Feb

LLY

Eli Lilly

$119.59

-0.175 (-0.15%)

16:34
12/08/19
12/08
16:34
12/08/19
16:34
Hot Stocks
Eli Lilly presents interim clinical data from LOXO-305 dose escalation trial »

Eli Lilly announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 17

    Dec

  • 30

    Jan

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

16:32
12/08/19
12/08
16:32
12/08/19
16:32
Hot Stocks
Bristol-Myers announces data from multiple liso-cel studies at ASH meeting »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

QURE

uniQure

$66.06

1.5 (2.32%)

16:26
12/08/19
12/08
16:26
12/08/19
16:26
Hot Stocks
uniQure reports 1-year follow-up data from etranacogene dezaparvovec study »

uniQure announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.